Instil Bio, Inc. announced significant clinical progress for IMM2510/SYN-2510 in China, with its collaborator ImmuneOnco Biopharmaceuticals. ImmuneOnco reported that the first patient has been dosed in its Phase 1b/2 clinical trial evaluating IMM2510/SYN-2510 in combination with chemotherapy for patients with advanced non-small cell lung cancer (NSCLC). This trial plans to enroll first-line patients.
ImmuneOnco anticipates presenting initial clinical data from this trial, including data for first-line NSCLC patients, as early as the second half of 2025. This data is expected to be valuable in advancing the development of IMM2510/SYN-2510 in NSCLC.
Instil also stated its plan to target enrollment of first-line NSCLC patients in a potential initial U.S. clinical trial of SYN-2510/IMM2510 combined with chemotherapy. This U.S. trial is expected to initiate in the second half of 2025, contingent upon obtaining the necessary regulatory approvals.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.